Rheumatoid Arthritis Treatment Guidelines

Initial Treatment Strategy

The American College of Rheumatology recommends starting methotrexate immediately as first-line therapy, optimized to 20-25 mg weekly, and escalating treatment every 3 months if moderate or high disease activity persists, with the goal of achieving remission or low disease activity 1
Methotrexate is the cornerstone of RA treatment and should be initiated as soon as the diagnosis is made, with the optimal dose being 20-25 mg weekly (oral or subcutaneous) with folic acid supplementation, according to the European League Against Rheumatism 2, 3, 1
For patients with contraindications or intolerance to methotrexate, alternative conventional synthetic DMARDs include leflunomide, sulfasalazine, and hydroxychloroquine, as recommended by the American College of Rheumatology 1, 3
Short-term glucocorticoids (low to moderate doses) can be added during initial treatment to bridge symptom control while DMARDs take effect, but must be tapered rapidly and discontinued within 1-2 years to avoid serious adverse effects, according to the European League Against Rheumatism 3, 1

The American College of Rheumatology recommends reassessing disease activity every 3 months using validated measures (SDAI or CDAI), and escalating therapy immediately if the patient has not achieved low disease activity or remission 2, 1
If poor prognostic features are present, adding a biologic DMARD (TNF inhibitor preferred) combined with methotrexate is recommended, according to the European League Against Rheumatism 2, 3, 1
If poor prognostic features are absent, adding combination conventional synthetic DMARD therapy or switching to another conventional synthetic DMARD is recommended, as suggested by the American College of Rheumatology 2, 3, 1

The American College of Rheumatology recommends first-line biologic therapy to be a TNF inhibitor (adalimumab, certolizumab, etanercept, golimumab, or infliximab) combined with methotrexate, which reduces signs and symptoms, inhibits structural damage progression, and improves physical function 2, 3, 1
Alternative first-line biologics include tocilizumab (IL-6 receptor antagonist), which can be used as monotherapy or combined with methotrexate, according to the European League Against Rheumatism 1

The American College of Rheumatology recommends mandatory screening before initiating any biologic DMARD, including tuberculosis testing, hepatitis B and C screening, and assessment for active infections, congestive heart failure, and history of malignancy 2, 4, 1
Patients on biologics have an increased risk of serious infections, and biologic therapy should be discontinued immediately if a serious infection develops, as recommended by the European League Against Rheumatism 2, 1

The American College of Rheumatology recommends careful consideration of biologic selection for patients with hepatitis, heart failure (NYHA Class III-IV), lymphoproliferative disorders, previous serious infections, or recent malignancy (within 5 years) 1
Rituximab may be preferred in patients with a history of lymphoproliferative malignancy or previously treated solid malignancy, according to the European League Against Rheumatism 1

The American College of Rheumatology recommends considering cautious de-escalation of therapy for patients achieving sustained remission (at least 6 months of low disease activity), with approximately 15-25% of patients potentially achieving sustained drug-free remission 1, 5
Factors associated with sustained drug-free remission include shorter symptom duration before treatment, absence of rheumatoid factor or anti-CCP antibodies, lower disease activity before achieving remission, and less baseline disability, as suggested by the European League Against Rheumatism 1, 5